Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 prophylaxis (excluding children) meta-analysis

C4591031- first boost
  NCT04955626		 RCTfirst booster doseComirnaty (tozinameran - Pfizer/BIONTECH)COVID-19 prophylaxis (excluding children)low
5081/5044 conclusif
  • demonstrated 95 % decrease in confirmed COVID (any severity) (PE) with a high degree of certainty due to low risk of bias
C4591031- first boost
  NCT04955626		 RCTfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)low
5081/5044 conclusif
  • demonstrated 95 % decrease in confirmed COVID (any severity) (PE) with a high degree of certainty due to low risk of bias
Pfizer/BioNTech Booster study
  NCT04713553		 RCTfirst booster doseComirnaty (tozinameran - Pfizer/BIONTECH)COVID-19 prophylaxis (excluding children)NA
-/- no results
    Observed relative vaccine efficacy of 95.6% (95% CI: 89.3, 98.6). The adverse event profile was generally consistent with other clinical safety data for the vaccine, with no safety concerns identified (press release).
    Pfizer/BioNTech Booster study
          NCT04713553    		 RCTfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)NA
    		-/- no results
      Observed relative vaccine efficacy of 95.6% (95% CI: 89.3, 98.6). The adverse event profile was generally consistent with other clinical safety data for the vaccine, with no safety concerns identified (press release).
      COVI3 OBSfirst booster doseComirnaty (tozinameran - Pfizer/BIONTECH)COVID-19 prophylaxis (excluding children)NA
      		-/- suggested
      • suggested 93 % decrease in confirmed COVID (any severity) (PE)
      • suggested 93 % decrease in symptomatic Covid-19
      COVI3 OBSfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)NA
      		-/- suggested
      • suggested 93 % decrease in confirmed COVID (any severity) (PE)
      • suggested 93 % decrease in symptomatic Covid-19
      McConeghy OBSfirst booster dosemRNA vaccineCOVID-19 prophylaxis (excluding children)NA
      		-/- suggested
      • suggested 97 % decrease in deaths,deaths
      • suggested 82 % decrease in hospitalization or death,hospitalization or death
      • suggested 51 % decrease in confirmed COVID (any severity),confirmed COVID (any severity)
      • suggested 58 % decrease in confirmed COVID (any severity),confirmed COVID (any severity)
      McConeghy OBSfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)NA
      		-/- suggested
      • suggested 97 % decrease in deaths,deaths
      • suggested 82 % decrease in hospitalization or death,hospitalization or death
      • suggested 51 % decrease in confirmed COVID (any severity),confirmed COVID (any severity)
      • suggested 58 % decrease in confirmed COVID (any severity),confirmed COVID (any severity)
      Kislaya OBSfirst booster doseComirnaty (tozinameran - Pfizer/BIONTECH)COVID-19 prophylaxis (excluding children)NA
      		-/- suggested
      • suggested 69 % decrease in confirmed COVID (any severity)
      Kislaya OBSfirst booster doseVaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)COVID-19 prophylaxis (excluding children)NA
      		-/- suggested
      • suggested 64 % decrease in confirmed COVID (any severity)
      Kislaya OBSfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)NA
      		-/- suggested
      • suggested 69 % decrease in confirmed COVID (any severity)
      • suggested 64 % decrease in confirmed COVID (any severity)
      Bar-On OBSfirst booster doseComirnaty (tozinameran - Pfizer/BIONTECH)COVID-19 prophylaxis (excluding children)NA
      		-/- suggested
      • suggested 91 % decrease in confirmed COVID (any severity),confirmed COVID (any severity)
      Bar-On OBSfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)NA
      		-/- suggested
      • suggested 91 % decrease in confirmed COVID (any severity),confirmed COVID (any severity)
      Accorsi OBSfirst booster dosecontrolCOVID-19 prophylaxis (excluding children)NA
      		-/- no results
        Comparison of 2 Doses vs Unvaccinated by Time Since Vaccination (graphical presentation) : The upper bound of the 95% CI was consistently greater than 1 starting at 3 months after second dose for BNT162b2 and at 6 months after second dose for mRNA-1273
        Accorsi OBSfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)NA
        		-/- no results
          Comparison of 2 Doses vs Unvaccinated by Time Since Vaccination (graphical presentation) : The upper bound of the 95% CI was consistently greater than 1 starting at 3 months after second dose for BNT162b2 and at 6 months after second dose for mRNA-1273
          Abu-Raddad OBSfirst booster doseComirnaty (tozinameran - Pfizer/BIONTECH)COVID-19 prophylaxis (excluding children)NA
          		-/- suggested
          • suggested 77 % decrease in hospitalization or death
          • suggested 49 % decrease in symptomatic Covid-19,confirmed COVID (any severity)
          Abu-Raddad OBSfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)NA
          		-/- suggested
          • suggested 77 % decrease in hospitalization or death
          • suggested 49 % decrease in symptomatic Covid-19,confirmed COVID (any severity)
          • suggested 47 % decrease in symptomatic Covid-19,confirmed COVID (any severity)
          Abu-Raddad OBSfirst booster doseSpikevax (Moderna mRNA-1273 COVID-19 vaccine)COVID-19 prophylaxis (excluding children)NA
          		-/- suggested
          • suggested 47 % decrease in symptomatic Covid-19,confirmed COVID (any severity)
          Arbel OBSfirst booster doseComirnaty (tozinameran - Pfizer/BIONTECH)COVID-19 prophylaxis (excluding children)serious
          		758118/85090 suggested
          • suggested 90 % decrease in deaths,deaths (PE) but with a low degree of certainty due to high risk of bias
          Arbel OBSfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)serious
          		758118/85090 suggested
          • suggested 90 % decrease in deaths,deaths (PE) but with a low degree of certainty due to high risk of bias
          Barda OBSfirst booster doseComirnaty (tozinameran - Pfizer/BIONTECH)COVID-19 prophylaxis (excluding children)NA
          		728321/728321 suggested
          • suggested 81 % decrease in deaths
          • suggested 93 % decrease in hospitalization (PE)
          Barda OBSfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)NA
          		728321/728321 suggested
          • suggested 81 % decrease in deaths
          • suggested 93 % decrease in hospitalization (PE)
          Mattiuzzi OBSfirst booster dosecontrolCOVID-19 prophylaxis (excluding children)NA
          		-/- suggested
          • suggested 85 % decrease in confirmed COVID (any severity)
          • suggested 85 % decrease in hospitalization
          Mattiuzzi OBSfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)NA
          		-/- suggested
          • suggested 65 % decrease in confirmed COVID (any severity)
          • suggested 69 % decrease in hospitalization
          Ontario (Buchan) OBSfirst booster dosecontrolCOVID-19 prophylaxis (excluding children)NA
          		-/- suggested
          • suggested 37 % decrease in confirmed COVID (any severity)
          Patalon OBSfirst booster doseComirnaty (tozinameran - Pfizer/BIONTECH)COVID-19 prophylaxis (excluding children)NA
          		-/- suggested
          • suggested 85 % decrease in confirmed COVID (any severity)
          • suggested 92 % decrease in hospitalization
          Patalon OBSfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)NA
          		-/- suggested
          • suggested 85 % decrease in confirmed COVID (any severity)
          • suggested 92 % decrease in hospitalization
          Tenforde OBSfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)NA
          		-/- suggested
          • suggested 82 % decrease in hospitalization
          Tenforde OBSfirst booster dosecontrolCOVID-19 prophylaxis (excluding children)NA
          		-/- suggested
          • suggested 97 % decrease in confirmed COVID (any severity)
          Tenforde OBSfirst booster dosemRNA vaccineCOVID-19 prophylaxis (excluding children)NA
          		-/- suggested
          • suggested 82 % decrease in hospitalization
          England (Andrews) OBSfirst booster dosecontrolCOVID-19 prophylaxis (excluding children)NA
          		581/130867 suggested
          • suggested 75 % decrease in symptomatic Covid-19,confirmed COVID (any severity)
          • suggested 71 % decrease in symptomatic Covid-19,confirmed COVID (any severity)
          Patalon OBSfirst booster doseComirnaty (tozinameran - Pfizer/BIONTECH)COVID-19 prophylaxis (excluding children)NA
          		-/- suggested
          • suggested 79 % decrease in confirmed COVID (any severity)
          Patalon OBSfirst booster dosecomplete primary vaccine seriesCOVID-19 prophylaxis (excluding children)NA
          		-/- suggested
          • suggested 79 % decrease in confirmed COVID (any severity)
          Sisonke 2 (booster)
                      NCT05148845          		 OBSfirst booster dosecontrolCOVID-19 prophylaxis (excluding children)NA
          		-/- suggested
          • suggested 85 % decrease in hospitalization

          PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
          Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

           

          - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons